Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11,773 Mln
Revenue (TTM)
$345,831 Mln
Net Profit (TTM)
$55,684 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
19.6
P/B Ratio
3
Industry P/E
24.44
EV/EBITDA
10.9
Div. Yield
0.7 %
Debt to Equity
0.1
Book Value
$--
EPS
$67.9
Face value
--
Shares outstanding
832,591,130
CFO
₹332,484.00 Mln
EBITDA
₹487,123.00 Mln
Net Profit
₹243,887.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy's Laboratories - ADR
| -4.2 | -8.5 | -5.5 | -1.9 | 7.3 | 2.4 | 4.1 |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy's Laboratories - ADR
| -11.1 | 13.3 | 34.5 | -20.9 | -8.2 | 75.7 | 7.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active... Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
Co-Chairman, MD & Member of Management Council
Mr. Gunupati Venkateswara Prasad B.E.
Co-Chairman, MD & Member of Management Council
Mr. Gunupati Venkateswara Prasad B.E.
Headquarters
Hyderabad
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Dr Reddy's Laboratories Ltd - ADR is $13.45 (NYSE) as of 24-Mar-2026 16:00 EDT. Dr Reddy's Laboratories Ltd - ADR has given a return of 7.27% in the last 3 years.
The P/E ratio of Dr Reddy's Laboratories Ltd - ADR is 19.64 times as on 20-Mar-2026, a 20 discount to its peers’ median range of 24.44 times.
The P/B ratio of Dr Reddy's Laboratories Ltd - ADR is 2.97 times as on 20-Mar-2026, a 48 discount to its peers’ median range of 5.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.19
|
0.03
|
|
2024
|
1.10
|
0.22
|
|
2023
|
1.05
|
0.21
|
|
2022
|
1.97
|
0.24
|
|
2021
|
219.78
|
21.56
|
The 52-week high and low of Dr Reddy's Laboratories Ltd - ADR are Rs 16.17 and Rs 12.26 as of 25-Mar-2026.
Dr Reddy's Laboratories Ltd - ADR has a market capitalisation of $ 11,773 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Dr Reddy's Laboratories Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.24
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.